| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Wednesday, November 15, 2023 7:05:55 PM
And you're an anonymous person, who says he doesn't own shares and spends years and years, every day, 24-7-365 posting negative comments on this treatment, because, apparently you claim you're "helping" us shareholders, which only shareholders read or post here. But the shareholders mostly appear not to want that kind of help. There are some who claim to be shareholders who ALSO have nothing good to say, but we all know they have had remedies for years and opportunities to exit at a very substantial profit, if they knew what they were doing, and were honest, but they chose not to do so.
I still remain very substantially up on this investment. And nothing suggests anything like what you state. Further, you've been a promoter of Optune, which apparently did exactly what you claim here, but you never thought to say it... they failed their Phase 3.
Optune was approved with zero OS benefit, despite OS being the primary endpoint. (EF11 trial). That trial failed by definition, whereas the DCVax-L Phase 3 met both of the prespecified primary endpoints in the SAP. :)
But you'll keep repeating your lies, because that is what you do.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173102434
exwannabe
Re: supersteve13 post# 643251
Thursday, October 26, 2023 4:32:02 PM
Post# of 647903
Congrats SuperSh, you are right for once.
Unlike you and your fellow clowns, I will admit when I was wrong and not just reply with insults.
Good luck with this POS stock.
Another poster's post, but I seem not to have the link handy.
Keep these facts in mind when Ex repeats his lies. :)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173101149
Yes, re Optune, there was basically no significant OS benefit, and that WAS in fact the primary measure, and yet it was approved…and the same shorts constantly post nonsense here about DCVax-L.
https://clinicaltrials.gov/study/NCT00379470
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173101856
Ex can you show how PFS was met/ succeeded in the EF11 trial? Please don’t lie about PFS being the primary endpoint again while doing so. Thanks! :)
https://www.ejcancer.com/article/S0959-8049(12)00352-8/fulltext
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
